News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

December 3, 2024

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 3rd December 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall have four members, in accordance with the applicable instructions resolved by the Annual General Meeting 2020. The three largest shareholders who are registered with Euroclear Sweden AB on…

May 3, 2022

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (publ)

STOCKHOLM, Sweden, 3[rd] May 2022: The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (“Lipidor” or the “Company”) are hereby given notice…

April 28, 2022

Lipidor AB (publ) publishes annual report for 2021

STOCKHOLM, Sweden, 28th April 2022 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the…

March 25, 2022

Lipidor strengthens its operational team and recruits Supply Chain & Operations Manager

STOCKHOLM, Sweden, 25 March 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) is announcing that the company has strengthened…

February 23, 2022

Lipidor AB (publ) publishes year-end report for 2021

STOCKHOLM, Sweden, 23 February 2022 – Today, Lipidor AB publishes its year-end report for the period 1 January – 31 December 2021.

January 26, 2022

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis

STOCKHOLM, Sweden, 26[th] January 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have…

December 17, 2021

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, 17[th] December 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for…

December 9, 2021

Lipidor presents Nomination Committee

STOCKHOLM, 9[th] December 2021 – In accordance with the current nomination committee instructions for Lipidor AB (publ) (Nasdaq First North Growth Market:…

November 25, 2021

Lipidor publishes interim report for period 1 January – 30 September and Q3 2021

STOCKHOLM, Sweden, 25[th] November 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period…

October 29, 2021

Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor’s AKVANO[®] technology for medicinal cannabis products

Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with…

October 19, 2021

Warrant holders exercise all warrants in Lipidor’s incentive program 2018/2021

STOCKHOLM, Sweden, 19 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company’s LTI 2018/2021,…